Effects of Epicatechin-rich Cocoa on Collagen Synthesis (coca-dose)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03214133|
Recruitment Status : Recruiting
First Posted : July 11, 2017
Last Update Posted : April 11, 2019
|Condition or disease||Intervention/treatment||Phase|
|Collagen Synthesis||Other: Epicatechin-rich cocoa dose response Other: Epicatechin-rich cocoa vs placebo on performance||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Crossover Assignment|
|Intervention Model Description:||Arm 1 of the project will employ a randomized single-blinded crossover design with subjects completing all 4 of the epicatechin-rich chocolate trials (0, 1, 2 and 3 mg.kg-1). Arm 2 will use a randomized parallel double-blind design with neither the subjects nor the investigators knowing who is on which treatment (optimized epicatechin-rich chocolate dose or Dutch processed/epicatechin depleted placebo.|
|Masking:||Double (Participant, Investigator)|
Alkalized (0.01 mg epicatechin/g) ) and non alkalized cocoa (4.1 mg epicaetchin/g) will be mixed in various ratios to achieve the desired 0, 1, 2, 3 mg/ kg body mass but maintaining equally weighed dose of cocoa for each intervention.
For Arm 2, the same quantity of either alkalized or non alkalized cocoa will be given to achieve the optimized dosed of epicatechin.
|Official Title:||Determining an Optimal Dose of Epicatechin-Rich Chocolate and Its Effect on Performance|
|Actual Study Start Date :||May 23, 2017|
|Estimated Primary Completion Date :||February 6, 2020|
|Estimated Study Completion Date :||February 6, 2020|
Experimental: Epicatechin Dose Response
This arm will investigate varying doses of epicatchin on procollagen type I N-terminal propeptide (PINP) at varying doses CON, 1, 2, 3 mg/kg body mass.
Other: Epicatechin-rich cocoa dose response
Subjects consume randomized doses of 0, 1, 2, 3 mg epicatechin/kg from epicatechin-rich cocoa. The optimal dose of epicatechin-rich chocolate will be the dose which have the greatest increase PNIP levels.
Placebo Comparator: Epicatechin-rich cocoa on performance
Athletes will ingest the optimized dose of epicatechin-rich cocoa vs placebo alongside maximum power training to determine if this nutritional intervention results in a greater increase in RFD and performance than maximum power training alone.
Other: Epicatechin-rich cocoa vs placebo on performance
An optimized dose of epictechin-rich cocoa or placebo will be given for 3 weeks alongside a prescribed power-based training program. In a randomized parallel design the effect of the optimal dose of epicatechin-rich chocolate, compared to placebo, on maximal isometric squat force, RFD, and jump testing will be quantified.
- Epicatechin-rich cocoa dose response [ Time Frame: ~26 days ]investigating effects doses of 0, 1, 2, 3 mg epicatechin/kg/day procollagen type I N-terminal propeptide (PINP) in the blood after 5 days of supplementation with 2-day wash out between.
- Effect of the optimized dose of epicatechin-rich cocoa on performance [ Time Frame: ~22 days ]Performance measures (of rate of force development) will be quantified for 3 weeks alongside the ingestion of an optimized dose of epicatechin-rich cocoa vs placebo.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03214133
|Contact: Dana M Lis, PhDemail@example.com|
|Contact: Keith Baar, PhDfirstname.lastname@example.org|
|United States, California|
|Neurobiology, Physiology & Behaviour||Recruiting|
|Davis, California, United States, 95616|
|Contact: Keith Baar, PhD 530-400-2188 email@example.com|
|Contact: Dana M Lis, PhD 530-304-5873 firstname.lastname@example.org|
|Principal Investigator:||Keith Baar, PhD||UC Davis|